06 Nov, EOD - Indian

SENSEX 80378.13 (1.13)

Nifty 50 24484.05 (1.12)

Nifty Bank 52317.4 (0.21)

Nifty IT 42039.5 (3.99)

Nifty Midcap 100 57355.8 (2.21)

Nifty Next 50 71389.8 (2.28)

Nifty Pharma 22920.35 (1.14)

Nifty Smallcap 100 18906.1 (2.18)

06 Nov, EOD - Global

NIKKEI 225 39480.67 (2.61)

HANG SENG 20538.38 (-2.23)

S&P 5970.75 (2.52)

Login/Signup
LOGIN HERE
Cancel

Torrent Pharmaceuticals Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 500420 | NSE Symbol : TORNTPHARM | ISIN : INE685A01028 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
10-Oct-2024 25-Oct-2024 Accounts TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-24. Results Q2 FY 2024-25. (As Per BSE Announcement dated on 25.10.2024)
05-Jul-2024 23-Jul-2024 Quarterly Results TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2024 inter alia to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Tuesday 23-Jul-24 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter ended on 30-Jun-24. Outcome of Board Meeting Dated 23-07-2024. (As Per BSE Announcement dated on 23.07.2024)
10-May-2024 24-May-2024 Final Dividend TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2024 inter alia to consider and approve We would like to inform you that: 1. A meeting of the Board of Directors will be held on Friday 24-May-24 inter alia to consider and approve the Audited Financial Results of the Company for the year ended on 31-Mar-24. 2. In the above meeting the Board would also consider the following: i. Recommendation of final dividend if any on the equity shares of the Company for the year 2023-24. ii. Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes. If approved by the Board of Directors the said item will be placed for Shareholders approval in the ensuing Annual General Meeting. Kindly take note of the above. Outcome of Board meeting dated 24-May-24 Results (As Per BSE Announcement dated on 24.05.2024)
12-Jan-2024 02-Feb-2024 Quarterly Results TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2024 inter alia to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Friday 02-Feb-24 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on 31-Dec-23. The Board would also consider payment of Interim Dividend for the year 2023-24. Board declared an interim dividend of Rs. 22/- (440%) per equity share of Rs. 5/- fully paid up. The dividend is expected to be paid/ dispatched on or around 23rd February, 2024. The Board of Directors acceded to the desire of Sudhir Mehta to step down as the Director of the Company while continuing as Chairman Emeritus effective from 1st Apr-24. (As Per BSE Bulletin Dated on 02.02.2024)
09-Oct-2023 23-Oct-2023 Quarterly Results TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2023 inter alia to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Monday 23-Oct-23 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-23. Financial results for quarter and half year ended 30-sep-23 (As per BSE Announcement Dated on 23/10/2023)
15-Jul-2023 07-Aug-2023 Quarterly Results TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2023 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter ended on 30-Jun-23. TORRENT PHARMACEUTICALS LIMITED has informed BSE about Board Meeting to be held on 07 Aug 2023 to consider financial statements for the period ended June 2023. Financial results. Submission / Intimation u/r 30 of SEBI (LODR) Regulation, 2015 - Financial Result for quarter ended 30th June, 2023 Board has at its meeting held today approved, inter alia, the Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with limited review report of the Company for the quarter ended 30th June, 2023. The said financial results are enclosed herewith. (As Per BSE Announcement Dated on 07.08.2023)
16-May-2023 30-May-2023 Accounts TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve We would like to inform you that: 1. A meeting of the Board of Directors will be held on Tuesday 30-May-23 inter alia to consider and approve the Audited Financial Results of the Company for the year ended on 31-Mar-23. 2. In the above meeting the Board would also consider the following: i. Recommendation of final dividend if any on the equity shares of the Company for the year 2022-23. ii. Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes. If approved by the Board of Directors the said item will be placed for Shareholders approval in the ensuing Annual General Meeting. Kindly take note of the above. Board Recommended to the members a final dividend of ? 8/- (160%) per equity share of ? 5 each. The final dividend amount, if declared by the Shareholders, is proposed to be paid / dispatched on or around 14th August, 2023. Earlier an interim dividend of ? 14/- (280%) per equity share was paid during the last quarter. (As Per BSE Announcement Dated on 30.05.2023)
12-Jan-2023 25-Jan-2023 Quarterly Results TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2023 inter alia to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Wednesday 25-Jan-23 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on 31-Dec-22. The Board would also consider payment of Interim Dividend for the year 2022-23. Board declared an interim dividend of 14/- (280 %) per equity share of 5/- fully paid up. The dividend is expected to be paid/ dispatched on or around 14th February, 2023. (As Per BSE Bulletin Dated on 25.01.2023) Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') (As per BSE Announcement Dated on 25/01/2023)
15-Dec-2022 21-Dec-2022 Scheme of Amalgamation Intimation of the Closure of Trading Window as per Company''s Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons Intimation for approval of scheme of amalgamation of Curatio Health Care (I) Private Limited with Company (As per BSE Announcement Dated on 21/12/2022)
04-Oct-2022 21-Oct-2022 Quarterly Results TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/10/2022 inter alia to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Friday 21-Oct-22 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-22. Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') (As per BSE Announcement Dated on 21/10/2022)
11-Jul-2022 29-Jul-2022 Quarterly Results TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2022 inter alia to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Friday 29-Jul-22 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter ended on 30-Jun-22. Appointment of Aman Mehta as Whole-time Director of the Company Submission/ Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') Appointment of Manish Choksi as Independent Director of the Company Appointment of Company Secretary and Compliance Officer (As per BSE Announcement Dated on 29/07/2022)
06-May-2022 25-May-2022 Final Dividend TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2022 inter alia to consider and approve 1. A meeting of the Board of Directors will be held on Wednesday 25-May-22 inter alia to consider and approve the Audited Financial Results of the Company for the year ended on 31-Mar-22. 2. In the above meeting the Board would also consider the following: i. Recommendation of final dividend if any on the equity shares of the Company for the year 2021-22. ii. Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes. If approved by the Board of Directors the said item will be placed for Shareholders approval in the ensuing Annual General Meeting. TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2022 ,inter alia, to consider and approve In furtherance to our earlier communication dated 6th May, 2022 with respect to intimation of the date of the Board meeting scheduled to be held on 25th May, 2022, we would like to inform that the Board of Directors in the said meeting would also consider the proposal for issuance of Bonus shares to the shareholders of the Company. (As Per BSE Announcement Dated on 21/05/2022) Torrent Pharmaceuticals Ltd has informed BSE that the Board has at its meeting held on May 25, 2022, approved / recommended, inter alia, the following: - Issue of Bonus shares in the ratio of 1:1 i.e. one equity share for each fully paid up equity share held as on record date fixed for the purpose. Consequent to the bonus issue, the total paid up share capital will be Rs. 169.22 Crores from the existing Rs. 84.62 Crores. The bonus issue of equity shares is subject to the approval of the members through Postal Ballot and any other applicable statutory and regulatory approvals, as may be required. Disclosure pursuant to Regulation 30 read with Schedule III and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), 2015, ('Listing Regulations') Disclosure pursuant to Regulation 30 of (Listing Obligations and Disclosure Requirements), 2015, ('Listing Regulations') Recommended to the members to obtain enabling approval for issuance of Equity Shares including Convertible Bonds/ Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes for an amount not exceeding Rs. 5,000 crores in the upcoming Annual General Meeting of the Company. (As Per BSE Announcement Dated on 25.05.2022)
11-May-2022 11-May-2022 Change in Directors Appointment of Dr. Maurice Chagnaud as an Additional and Independent Director of the Company
10-Jan-2022 25-Jan-2022 Quarterly Results TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2022 inter alia to consider and approve We would like to inform you that the meeting of the Board of Directors will be held on Tuesday 25-Jan-22 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on 31-Dec-21. The Board would also consider payment of Interim Dividend for the year 2021-22. We would like to inform that the Board has at its meeting held today approved an interim dividend of Rs. 25/- (500 %) per equity share of Rs. 5/- fully paid up. The dividend is expected to be paid / dispatched on or around 11th February, 2022. We would like to inform that the Board has at its meeting held today approved, inter-alia, the following: 1) Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with the limited review report of the Company for the quarter and nine months ended on 31st December, 2021. The said financial results are enclosed herewith. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Unaudited Consolidated Financial Results for the quarter and nine months ended on 31st December, 2021. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com. A Press Release on Financial Results which is being submitted to the media is also enclosed herewith. (As Per BSE Announcement Dated on 25.01.2022)
11-Oct-2021 26-Oct-2021 Quarterly Results TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2021 ,inter alia, to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Tuesday, 26-Oct-21, inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-21. Outcome of Board Meeting dated 26-Oct-2021 (As per BSE Announcement Dated on 26/10/2021)
1 2